Literature DB >> 7946770

Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.

J D Gemmill1, K J Hogg, F G Dunn, A P Rae, W S Hillis.   

Abstract

OBJECTIVE: To evaluate the influence of pretreatment streptokinase resistance titre and the concentration of IgG antibodies to streptokinase on the efficacy of thrombolytic drugs containing streptokinase in restoring coronary patency in acute myocardial infarction.
DESIGN: Comparative observational study.
SETTING: City general hospital. PATIENTS: One hundred and twenty four previously unexposed patients presenting within six hours of onset of acute myocardial infarction.
INTERVENTIONS: Streptokinase, 1.5 MIU as intravenous infusion over 60 minutes (60 patients), or anistreplase, 30 units as intravenous injection over five minutes (64 patients). MAIN OUTCOME MEASURES: Pretreatment streptokinase resistance titre and concentration of IgG antibodies to streptokinase were measured in 96 and 124 patients respectively and coronary patency assessed angiographically at 90 minutes and 24 hours.
RESULTS: Pretreatment streptokinase resistance titre and concentrations of IgG antibodies to streptokinase were low and skewed towards higher values. Those patients with coronary occlusion at 24 hours had a significantly higher median streptokinase resistance titre (100 v 50 streptokinase IU ml-1, P = 0.02). There were trends towards a higher streptokinase resistance titre in those patients with coronary occlusion at 90 minutes (50 v 20 streptokinase IU ml-1, P = 0.06) and higher concentrations of IgG antibodies to streptokinase in those with coronary occlusion at both 90 minutes and 24 hours (1.53 v 0.925, P = 0.03; 1.65 v 1.04 micrograms streptokinase binding ml-1, P = 0.06). Coronary patency rates were similar in the two treatment groups.
CONCLUSIONS: In the range measured in previously unexposed patients the streptokinase resistance titre has a small, but significant, negative influence on the efficacy of streptokinase and anistreplase. This effect should be considered if retreatment with streptokinase or anistreplase is proposed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946770      PMCID: PMC1025505          DOI: 10.1136/hrt.72.3.222

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  19 in total

1.  [The effect of intravenously administered streptokinase on fibrinolysis and blood coagulation].

Authors:  E DEUTSCH; M FISCHER
Journal:  Thromb Diath Haemorrh       Date:  1960-06-15

2.  Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.

Authors:  R L Rothbard; P G Fitzpatrick; C W Francis; D M Caton; W B Hood; V J Marder
Journal:  Circulation       Date:  1985-03       Impact factor: 29.690

3.  Assessment of anti-streptokinase antibody levels in human sera using a microradioimmunoassay procedure.

Authors:  D M Moran; R Standring; E A Lavender; G S Harris
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

4.  Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody.

Authors:  A S Lew; T Neer; L Rodriguez; I L Geft; P K Shah; W Ganz
Journal:  J Am Coll Cardiol       Date:  1984-07       Impact factor: 24.094

5.  Thrombolytic therapy with streptokinase using a standard dosage scheme.

Authors:  M Verstraete; J Vermylen; A Amery; C Vermylen
Journal:  Br Med J       Date:  1966-02-19

6.  A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.

Authors:  J L Anderson; H W Marshall; J C Askins; J R Lutz; S G Sorensen; R L Menlove; F G Yanowitz; A D Hagan
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

Review 7.  Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.

Authors:  R Beresford; A Ward
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

8.  Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.

Authors:  M Been; D P de Bono; A L Muir; F E Boulton; R Fears; R Standring; H Ferres
Journal:  Int J Cardiol       Date:  1986-04       Impact factor: 4.164

9.  Identification of patients at risk for anaphylaxis due to streptokinase.

Authors:  M S Dykewicz; K G McGrath; R Davison; K J Kaplan; R Patterson
Journal:  Arch Intern Med       Date:  1986-02

10.  Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography.

Authors:  J W Kennedy; G G Gensini; G C Timmis; C Maynard
Journal:  Am J Cardiol       Date:  1985-04-01       Impact factor: 2.778

View more
  5 in total

1.  Antistreptokinase antibodies: implications for thrombolysis in a region with endemic streptococcal infection.

Authors:  N Blackwell; A Hollins; G Gilmore; R Norton
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

Review 2.  Criteria for drug usage review of thrombolytics in acute myocardial infarction.

Authors:  S McGlynn
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 3.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 4.  How safe is the readministration of streptokinase?

Authors:  H S Lee
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 5.  Pulmonary embolism--the role of thrombolytic therapy in its management.

Authors:  R S More; A Chauhan
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.